NEW YORK (TheStreet) -- Shares ofNeuralstem (CUR) continue to rise, up 6.25% to $2.89, in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) , which touched a one-year high on Friday. <\/p>\n
Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. The company describes NurOwn as an \"autologous, adult stem cell therapy technology\" designed to treat ALS, also known as Lou Gehrig's Disease. <\/p>\n
The company will host a conference call on Monday to discuss the results. <\/p>\n
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. <\/p>\n
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. <\/p>\n
Access the tool that DOMINATES the Russell 2000 and the S&P 500. <\/p>\n
Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. <\/p>\n
<\/p>\n
See the original post here:<\/p>\n
Neuralstem (CUR) Stock Rises Today as Brainstorm Cell Therapeutics Soars<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" NEW YORK (TheStreet) -- Shares ofNeuralstem (CUR) continue to rise, up 6.25% to $2.89, in morning trading Friday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) , which touched a one-year high on Friday. Brainstorm intends to release the final results from its Phase 2a trial of its stem cell therapy NurOwn on Monday. Continue reading